Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs
Corresponding Author
Giuseppe Milone
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Istituto Oncologico del Mediterraneo, Viagrande, Italy
Correspondence: Giuseppe Milone, Programma di Trapianto Emopoietico, Azienda Ospedaliera Universitaria, Policlinico Vittorio Emanuele, via Santa Sofia, 78 Catania, Italy.
E-mail: [email protected]
Search for more papers by this authorMassimo Martino
Programma Trapianto di Midollo, Ospedali Melacrino-Morelli, Reggio Calabria, Italy
Search for more papers by this authorAndrea Spadaro
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorSalvatore Leotta
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorAnnalia Di Marco
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorPotito Scalzulli
Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Search for more papers by this authorAlessandra Cupri
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorValentina Di Martina
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorElena Schinocca
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorEleonora Spina
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorGiovanni Tripepi
Clinical Epidemiology, IBIM-CNR, Reggio Calabria, Italy
Search for more papers by this authorCorresponding Author
Giuseppe Milone
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Istituto Oncologico del Mediterraneo, Viagrande, Italy
Correspondence: Giuseppe Milone, Programma di Trapianto Emopoietico, Azienda Ospedaliera Universitaria, Policlinico Vittorio Emanuele, via Santa Sofia, 78 Catania, Italy.
E-mail: [email protected]
Search for more papers by this authorMassimo Martino
Programma Trapianto di Midollo, Ospedali Melacrino-Morelli, Reggio Calabria, Italy
Search for more papers by this authorAndrea Spadaro
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorSalvatore Leotta
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorAnnalia Di Marco
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorPotito Scalzulli
Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Search for more papers by this authorAlessandra Cupri
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorValentina Di Martina
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorElena Schinocca
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorEleonora Spina
Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy
Search for more papers by this authorGiovanni Tripepi
Clinical Epidemiology, IBIM-CNR, Reggio Calabria, Italy
Search for more papers by this authorSummary
To date, no prospective study on Plerixafor ‘on-demand’ in combination with chemotherapy and granulocyte colony-stimulating factor (G-CSF) has been reported. We present an interim analysis of the first prospective study in which Plerixafor was administered on-demand in patients affected by multiple myeloma and lymphoma who received high dose cyclophosphamide or DHAP (dexamethasone, cytarabine, cisplatin) plus G-CSF to mobilize peripheral blood stem cells (PBSC). One hundred and two patients were evaluable for response. A cohort of 240 patients receiving the same mobilizing chemotherapy was retrospectively studied. Failure to mobilize CD34+ cells in peripheral blood was reduced by ‘on-demand’ strategy compared to conventional mobilization; from 13·0 to 3·0% (P = 0·004). Failure to harvest CD34+ cells 2 × 106/kg decreased from 20·9 to 4·0% (P = 0·0001). The on-demand Plerixafor strategy also resulted in a lower rate of mobilization failure (P = 0·03) and harvest failure (P = 0·0008) when compared to a ‘bias-adjusted set of controls’. Evaluation of economic costs of the two strategies showed that the overall cost of the two treatments were comparable when salvage mobilizations were taken into account. When in combination with cyclophosphamide or DHAP plus G-CSF, the ‘on-demand’ use of Plerixafor showed, in comparison to conventionally treated patients, a significant improvement in mobilization of PBSC with no increase in overall cost.
References
- Abhyankar, S., DeJarnette, S., Aljitawi, O., Ganguly, S., Merkel, D. & McGuirk, J. (2012) Arisk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of Plerixafor. Bone Marrow Transplantation, 47, 483–487.
- Attolico, I., Pavone, V., Ostuni, A., Rossini, B., Musso, M., Crescimanno, A., Martino, M., Iacopino, P., Milone, G., Tedeschi, P., Coluzzi, S., Nuccorini, R., Pascale, S., Di Nardo, E. & Olivieri, A. (2012) Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biology of Blood and Marrow Transplantation, 18, 241–249.
- Chabannon, C., Le Corroller, A.G., Viret, F., Eillen, C., Faucher, C., Moatti, J.P., Viens, P., Vey, N., Braud, A.C., Novakovitch, G., Ladaique, P., Stoppa, A.M., Camerlo, J., Genre, D., Maraninchi, D. & Blaise, D. (2003) Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dosechemotherapy and autologous hematopoietic cell transplantation. Leukemia, 17, 811–820.
- Chen, A.I., Bains, T., Murray, S., Knight, R., Shoop, K., Bubalo, J., Fowler, C., Slater, S. & Maziarz, R.T. (2012) Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplantation, 47, 1526–1529.
- Costa, L.J., Alexander, E.T., Hogan, K.R., Schaub, C., Fouts, T.V. & Stuart, R.K. (2011) Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplantation, 46, 64–69.
- Cuzick, J. (2005) Forest plots and the interpretation of subgroups. Lancet, 365, 1308.
- D'Addio, A., Curti, A., Worel, N., Douglas, K., Motta, M.R., Rizzi, S., Dan, E., Taioli, S., Giudice, V., Agis, H., Kopetzky, G., Soutar, R., Casadei, B., Baccarani, M. & Lemoli, R.M. (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplantation, 46, 356–363.
- DiPersio, J.F., Stadtmauer, E.A., Nademanee, A., Micallef, I.N., Stiff, P.J., Kaufman, J.L., Maziarz, R.T., Hosing, C., Früehauf, S., Horwitz, M., Cooper, D., Bridger, G. & Calandra, G. (2009a) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113, 5720–5726.
- DiPersio, J.F., Micallef, I.N., Stiff, P.J., Bolwell, B.J., Maziarz, R.T., Jacobsen, E., Nademanee, A., McCarty, J., Bridger, G. & Calandra, G. (2009b) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 4767–4773.
- Farina, L., Spina, F., Guidetti, A., Longoni, P., Ravagnani, F., Dodero, A., Montefusco, V., Carlo-Stella, C. & Corradini, P. (2013) Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte colony-stimulating factor: an algorithm for the pre-emptive use of Plerixafor. Leukemia and Lymphoma, doi: 10.3109/10428194.2013.802783.
- Gazitt, Y., Callander, N., Freytes, C.O., Shaughnessy, P., Liu, Q., Tsai, T.W. & Devore, P. (2000) Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. Journal Hematotherapy and Stem Cell Research, 9, 737–748.
- Horwitz, M.E., Chute, J.P., Gasparetto, C., Long, G.D., McDonald, C., Morris, A., Rizzieri, D.A., Sullivan, K.M. & Chao, N.J. (2012a) Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplantation, 47, 1051–1055.
- Horwitz, M.E., Long, G., Holman, P., Libby, E., Calandra, G.C. & Schriber, J.R. (2012b) Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors. Bone Marrow Transplantation, 47, 1283–1286.
- Hosing, C., Saliba, R.M., Ahlawat, S., Korbling, M., Kebriaei, P., Alousi, A., De Lima, M., Okoroji, J.G., McMannis, J., Qazilbash, M., Anderlini, P., Giralt, S., Champlin, R.E., Khouri, I. & Popat, U. (2009) Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American Journal of Hematology, 84, 335–337.
- Keating, G. (2011) Plerixafor a review of its use in stem cell mobilization in patients with Lymphoma or Multiple Myeloma. Drugs, 71, 1623–1647.
- Kuittinen, T., Nousiainen, T., Halonen, P., Mahlamaki, E. & Jantunen, E. (2004) Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation, 33, 907–912.
- Li, J., Hamilton, E., Vaughn, L., Graiser, M., Renfroe, H., Lechowicz, M.J., Langston, A., Prichard, J.M., Anderson, D., Gleason, C., Lonial, S., Flowers, C.R., Kaufman, J.L. & Waller, E.K. (2011) Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion, 51, 2175–2182.
- McQuaker, I.G., Haynes, A.P., Stainer, C., Anderson, S. & Russell, N.H. (1997) Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. British Journal of Haematology, 98, 228–233.
- Micallef, I.N., Sinha, S., Gastineau, D.A., Wolf, R., Inwards, D.J., Gertz, M.A., Hayman, S.R., Hogan, W.J., Johnston, P.B., Lacy, M.Q., Ansell, S.M., Buadi, F., Dingli, D., Dispenzieri, A., Litzow, M.R., Porrata, L.F., Winters, J.L. & Kumar, S. (2013) Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biology of Blood and Marrow Transplantation, 19, 87–93.
- Milone, G., Leotta, S., Indelicato, F., Mercurio, S., Moschetti, G., Di Raimondo, F., Tornello, A., Consoli, U., Guido, G. & Giustolisi, R. (2003) G-CSF alone versus cyclophosphamide plus G-CSF in PBSC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplantation, 31, 747–754.
- Milone, G., Martino, M., Leotta, S., Guidi, S., Saccardi, R., Mercurio, S., Avola, G., Camuglia, M.G., Iacona, F., Bartolozzi, B., Nozzoli, C., Liggeri, S., Disca, S., Iacopino, L. & Bosi, A. (2012) CD34+ mobilization & pbsc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. Drugs and Cell Therapies in Hematology, Suppl n1, 2012, 91–103.
10.4081/dcth.2012.18 Google Scholar
- Milone, G., Tripepi, G., Martino, M., Ancora, F., Bartolozzi, B., Spadaro, A., Nozzoli, C., La Fauci, A., Amico, I., Leotta, S., Poidomani, M., Irrera, G., Iacopino, P., Saccardi, R. & Bosi, A. (2013) Early measurement of CD34+ in peripheral blood after cyclophosphamide and G-CSF predicts later CD34+ mobilization failure and can be used as criteria for testing “on demand” use of plerixafor. Blood Transfusion, 11, 94–101.
- Olivieri, A., Marchetti, M., Lemoli, R., Tarella, C., Iacone, A., Lanza, F., Rambaldi, A. & Bosi, A. (2012) Proposed definition of poor mobilizer in lymphoma and multiple myeloma an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplantation, 47, 342–351.
- Ozsan, G.H., Micallef, I.N., Dispenzieri, A., Kumar, S., Lacy, M.Q., Dingli, D., Hayman, S.R., Buadi, F.K., Wolf, R.C., Gastineau, D.A., Hogan, W.J. & Gertz, M.A. (2012) Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. American Journal of Hematology, 87, 1–4.
- Pavone, V., Gaudio, F., Guarini, A., Perrone, T., Zonno, A., Curci, P. & Liso, V. (2002) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or DHAP regimen plus G-CSF in non Hodgkin's lymphoma. Bone Marrow Transplantation, 29, 285–290.
- Pusic, I., Jiang, S.Y., Landua, S., Uy, G.L., Rettig, M.P., Cashen, A.F., Westervelt, P., Vij, R., Abboud, C.N., Stockerl-Goldstein, K.E., Sempek, D.S., Smith, A.L. & DiPersio, J.F. (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation Biol Blood Marrow. Transplantation, 14, 1045–1056.
- Seggewiss, R., Buss, E.C., Herrmann, D., Goldschmidt, H., Ho, A.D. & Freuhauf, S. (2003) Kinetics of peripheral blood stem cell mobilization following G-CSF supported Chemotherapy. Stem Cells, 21, 568–574.
- Sinha, S., Gastineau, D., Micallef, I., Hogan, W., Ansell, S., Buadi, F., Dingli, D., Dispenzieri, A., Gertz, M., Greiner, C., Hayman, S., Inwards, D., Johnston, P., Lacy, M., Litzow, M., Porrata, L., Winters, J.L. & Kumar, S. (2011) Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation, 46, 943–949.
- Smith, V.R., Popat, U., Ciurea, S., Nieto, Y., Anderlini, P., Rondon, G., Alousi, A., Qazilbash, M., Kebriaei, P., Khouri, I., de Lima, M., Champlin, R. & Hosing, C. (2013) Just-in-time rescue plerixafor in combination with chemotherapy & granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. American Journal of Hematology, doi: 10.1002/ajh.23499.
- Stockerl-Goldstein, K.E., Reddy, S.A., Horning, S.F., Blume, K.G., Chao, N.F., Hu, W.W., Johnston, L.F., Long, G.D., Strober, S., Wong, R.M., Feiner, R.H., Kobler, S. & Negrin, R.S. (2000) Favorable treatment outcome in non-Hodgkin's lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biology of Blood and Marrow Transplantation, 6, 506–512.
- Stroncek, D.F., Clay, M.E., Herr, G., Smith, J., Jaszcz, W.B., Ilstrup, S. & McCullough, J. (1997) The kinetics of G-CSF mobilization of CD34+ cells in healthy people. Transfusion Medicine, 7, 19–24.
- Sugrue, M.W., Williams, K., Pollock, B.H., Khan, S., Peracha, S., Wingard, J.R. & Moreb, J.S. (2000) Characterization and outcome of “hard to mobilize”‘lymphoma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 39, 509–519.
- Wuchter, P., Ran, D., Bruckner, T., Schmitt, T., Witzens-Harig, M., Neben, K., Goldschmidt, H. & Ho, A.D. (2010) Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation, 16, 490–499.
Citing Literature
